AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21767798 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate to severe depression treatment
Number of subjects: 14
Study 21767798 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral therapy
Number of subjects: 14
Study 21767798 — intervention group
Group type: COMPARATOR
Intervention: Training and benchmark information
Number of subjects: 14
Study 19209097 — intervention group
Group type: EXPERIMENTAL
Intervention: MenACWY-CRM (2 doses at 2 and 4 months of age)
Number of subjects: 180
Study 19209097 — intervention group
Group type: EXPERIMENTAL
Intervention: MenACWY-CRM (booster dose at 12 months)
Number of subjects: 180
Study 16721464 — intervention group
Group type: COMPARATOR
Intervention: Control (no debonding/rebonding)
Number of subjects: 50
Study 16721464 — intervention group
Group type: EXPERIMENTAL
Intervention: Recycled brackets (aluminum oxide blasting)
Number of subjects: 50
Study 16721464 — intervention group
Group type: EXPERIMENTAL
Intervention: Recycled brackets (new brackets attached to previously bonded teeth)
Number of subjects: 50
Study 16721464 — intervention group
Group type: EXPERIMENTAL
Intervention: Recycled brackets (specialized company)
Number of subjects: 50
Study 16721464 — intervention group
Group type: EXPERIMENTAL
Intervention: Recycled brackets (silicon carbide stone grinding)
Number of subjects: 50
Study 12642956 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed prostheses on implants (upper jaw)
Number of subjects: 164
Study 12642956 — intervention group
Group type: EXPERIMENTAL
Intervention: Removable prostheses on implants
Number of subjects: 164
Study 12642956 — intervention group
Group type: COMPARATOR
Intervention: Natural dentition (control group)
Number of subjects: 164
Study 10721826 — intervention group
Group type: EXPERIMENTAL
Intervention: Photodynamic therapy using topically applied delta‐aminolevulinic acid
Number of subjects: 526
Study 10721826 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryotherapy
Number of subjects: 526
Study 10721826 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser-Doppler perfusion imaging technique
Number of subjects: 526
Study 10721826 — intervention group
Group type: COMPARATOR
Intervention: Recurrent lesions
Number of subjects: 526
Study 8958856 — intervention group
Group type: EXPERIMENTAL
Intervention: Lysine acetylsalicylate (LAS)
Number of subjects: 473
Study 8958856 — intervention group
Group type: COMPARATOR
Intervention: Paracetamol (PAR)
Number of subjects: 473
Study 1404352 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise treatment
Number of subjects: 31
Study 1404352 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived seriousness of hypercholesterolemia
Number of subjects: 31
Study 1404352 — intervention group
Group type: EXPERIMENTAL
Intervention: Expectation of benefit from treatment
Number of subjects: 31
Study 1404352 — intervention group
Group type: EXPERIMENTAL
Intervention: Depressed feelings of helplessness and hopelessness
Number of subjects: 31
Study 1404352 — intervention group
Group type: EXPERIMENTAL
Intervention: Perception of health status being under the control of chance or powerful others
Number of subjects: 31
Study 1404352 — intervention group
Group type: EXPERIMENTAL
Intervention: Older age
Number of subjects: 31
Study 3893185 — intervention group
Group type: EXPERIMENTAL
Intervention: 14-valent pneumococcal polysaccharide vaccine
Number of subjects: 3340
Study 3893185 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 3340
Study 31533777 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole (LTZ) 2.5 mg/day for 3 weeks
Number of subjects: 61
Study 31533777 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral metronomic vinorelbine (mVNB) 50 mg 3 days/week for 3 weeks
Number of subjects: 61
Study 31533777 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of LTZ and mVNB
Number of subjects: 61
Study 31533777 — intervention group
Group type: COMPARATOR
Intervention: LTZ
Number of subjects: 61
Study 31533777 — intervention group
Group type: COMPARATOR
Intervention: LTZ+mVNB
Number of subjects: 61
Study 29270828 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepped care
Number of subjects: 1012
Study 29270828 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 1012
Study 27539586 — intervention group
Group type: EXPERIMENTAL
Intervention: BEAT Cancer
Number of subjects: 222
Study 27539586 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 222
Study 25323062 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behaviour Therapy (CBT)
Number of subjects: 46
Study 25323062 — intervention group
Group type: COMPARATOR
Intervention: Anxiety Management (AM)
Number of subjects: 46
Study 22502772 — intervention group
Group type: EXPERIMENTAL
Intervention: Entropy group (visible entropy values)
Number of subjects: 70
Study 22502772 — intervention group
Group type: COMPARATOR
Intervention: Control group (invisible entropy values)
Number of subjects: 70
Study 22502772 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 70
Study 19969339 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol combination therapy
Number of subjects: 14
Study 19969339 — intervention group
Group type: COMPARATOR
Intervention: Budesonide alone
Number of subjects: 14
Study 19969339 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 18947348 — intervention group
Group type: EXPERIMENTAL
Intervention: Younger adults; mood-congruent gaze
Number of subjects: 0
Study 18947348 — intervention group
Group type: EXPERIMENTAL
Intervention: Older adults; mood-incongruent positive gaze
Number of subjects: 0
Study 15965894 — intervention group
Group type: EXPERIMENTAL
Intervention: Albuterol 2.5 mg nebulized
Number of subjects: 19
Study 15965894 — intervention group
Group type: COMPARATOR
Intervention: Placebo nebulized
Number of subjects: 19
Study 14727987 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimetazidine 20 mg, 3 times daily for 1 month
Number of subjects: 40
Study 14727987 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 10660274 — intervention group
Group type: EXPERIMENTAL
Intervention: Bath at 1 hour of age
Number of subjects: 80
Study 10660274 — intervention group
Group type: COMPARATOR
Intervention: Bath at 2 hours of age
Number of subjects: 80
Study 9007781 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibre-optic phototherapy
Number of subjects: 123
Study 9007781 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional daylight phototherapy
Number of subjects: 123
Study 9007781 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of both phototherapy types
Number of subjects: 123
Study 9007781 — intervention group
Group type: COMPARATOR
Intervention: Control group (unexposed infants)
Number of subjects: 123
Study 1381690 — intervention group
Group type: EXPERIMENTAL
Intervention: lignocaine‐dextran
Number of subjects: 20
Study 1381690 — intervention group
Group type: COMPARATOR
Intervention: lignocaine‐saline
Number of subjects: 20
Study 6388516 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostacyclin (PGI2) 25 ng/kg/min during CPB
Number of subjects: 50
Study 6388516 — intervention group
Group type: COMPARATOR
Intervention: Placebo during CPB
Number of subjects: 50
Study 29365333 — intervention group
Group type: EXPERIMENTAL
Intervention: Coenzyme Q10 (100 mg/day)
Number of subjects: 80
Study 29365333 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 28601610 — intervention group
Group type: EXPERIMENTAL
Intervention: OAC (omeprazole, amoxicillin, clarithromycin)
Number of subjects: 301
Study 28601610 — intervention group
Group type: EXPERIMENTAL
Intervention: OTMB (omeprazole, tetracycline, metronidazole, bismuth)
Number of subjects: 301
Study 28601610 — intervention group
Group type: EXPERIMENTAL
Intervention: OACB (omeprazole, amoxicillin, clarithromycin, bismuth)
Number of subjects: 301
Study 28601610 — intervention group
Group type: EXPERIMENTAL
Intervention: OA+OCM (omeprazole, amoxicillin, metronidazole)
Number of subjects: 301
Study 28601610 — intervention group
Group type: EXPERIMENTAL
Intervention: OA+OCMB (omeprazole, amoxicillin, metronidazole, bismuth)
Number of subjects: 301
Study 28601610 — intervention group
Group type: EXPERIMENTAL
Intervention: OA+OMDB (omeprazole, amoxicillin, metronidazole, doxycycline, bismuth)
Number of subjects: 301
Study 26385671 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain treatment protocol and education program
Number of subjects: 156
Study 26385671 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 156
Study 22035345 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrophobic acrylic IOL
Number of subjects: 46
Study 22035345 — intervention group
Group type: EXPERIMENTAL
Intervention: Silicone IOL
Number of subjects: 46
Study 22035345 — intervention group
Group type: EXPERIMENTAL
Intervention: PMMA IOL
Number of subjects: 46
Study 22035345 — intervention group
Group type: EXPERIMENTAL
Intervention: IOL dioptric power (Hydrophobic acrylic IOL)
Number of subjects: 46
Study 20880055 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib 200mg b.i.d. for 3 days
Number of subjects: 24
Study 20880055 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 19463308 — intervention group
Group type: EXPERIMENTAL
Intervention: Interceptor PLUS Coronary Filter System
Number of subjects: 797
Study 19463308 — intervention group
Group type: COMPARATOR
Intervention: Control distal-protection devices (GuardWire, FilterWire EZ)
Number of subjects: 797
Study 16927868 — intervention group
Group type: EXPERIMENTAL
Intervention: Conservative surgery (endocystectomy, omentoplasty with or without drainage)
Number of subjects: 32
Study 16927868 — intervention group
Group type: COMPARATOR
Intervention: Radical surgery (closed pericystectomy, open pericystectomy, wedge hepatic resection or segmentectomy)
Number of subjects: 32
Study 14523307 — intervention group
Group type: EXPERIMENTAL
Intervention: CAST (forearm immobilization for 21 days)
Number of subjects: 6
Study 14523307 — intervention group
Group type: COMPARATOR
Intervention: CONT (dominant arm, no immobilization)
Number of subjects: 6
Study 10770193 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 microg/kg x day recombinant human GH for 4 days followed by 10 microg/kg x day GH for another 4 days (Group A)
Number of subjects: 20
Study 10770193 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 microg/kg x day GH (Group B)
Number of subjects: 20
Study 10770193 — intervention group
Group type: COMPARATOR
Intervention: Age-matched controls
Number of subjects: 20
Study 9286529 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambulation at a mean of 2.5 hr after sheath removal (group 1)
Number of subjects: 323
Study 9286529 — intervention group
Group type: COMPARATOR
Intervention: Ambulation at a mean of 4.1 hr after sheath removal (group 2)
Number of subjects: 323
Study 7506161 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimesulide 100mg
Number of subjects: 134
Study 7506161 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimesulide 200mg
Number of subjects: 134
Study 7506161 — intervention group
Group type: EXPERIMENTAL
Intervention: Niflumic acid 250mg
Number of subjects: 134
Study 7506161 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 134
Study 3534005 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 61
Study 3534005 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxaprotiline
Number of subjects: 61
Study 3534005 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study 2557364 — intervention group
Group type: EXPERIMENTAL
Intervention: Coping skills training
Number of subjects: 96
Study 2557364 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactional therapy
Number of subjects: 96
Study 31900486 — intervention group
Group type: EXPERIMENTAL
Intervention: DNA and protein coadministration by needle/syringe
Number of subjects: 132
Study 31900486 — intervention group
Group type: EXPERIMENTAL
Intervention: DNA administration by Biojector
Number of subjects: 132
Study 31900486 — intervention group
Group type: EXPERIMENTAL
Intervention: DNA and protein coadministration with DNA given by Biojector
Number of subjects: 132
Study 31900486 — intervention group
Group type: COMPARATOR
Intervention: Placebo by needle/syringe
Number of subjects: 132
Study 31900486 — intervention group
Group type: COMPARATOR
Intervention: Placebo by Biojector
Number of subjects: 132
Study 31900486 — intervention group
Group type: EXPERIMENTAL
Intervention: DNA prime, protein boost by needle/syringe
Number of subjects: 132
Study 31900486 — intervention group
Group type: EXPERIMENTAL
Intervention: DNA prime, protein boost with DNA given by Biojector
Number of subjects: 132
Study 31241441 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic therapy and vitamin D
Number of subjects: 60
Study 31241441 — intervention group
Group type: COMPARATOR
Intervention: Antibiotic only
Number of subjects: 60
Study 29676139 — intervention group
Group type: EXPERIMENTAL
Intervention: Xinling Wan (two pills each time, three times daily for 4 weeks)
Number of subjects: 232
Study 29676139 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 232
Study 29676139 — intervention group
Group type: EXPERIMENTAL
Intervention: Xinling Wan
Number of subjects: 232
Study 28889258 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline
Number of subjects: 205
Study 28889258 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 205
Study 26284748 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 15
Study 26284748 — intervention group
Group type: COMPARATOR
Intervention: Selective Serotonin Reuptake Inhibitors (SSRIs)
Number of subjects: 15
Study 23633698 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium nitrate dentifrice
Number of subjects: 304
Study 23633698 — intervention group
Group type: EXPERIMENTAL
Intervention: Sealant
Number of subjects: 304
Study 23633698 — intervention group
Group type: EXPERIMENTAL
Intervention: Resin-based composite restoration
Number of subjects: 304
Study 21165822 — intervention group
Group type: EXPERIMENTAL
Intervention: High-definition endoscopy (HDE)
Number of subjects: 48
Study 21165822 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrow-band imaging (NBI)
Number of subjects: 48
Study 21165822 — intervention group
Group type: COMPARATOR
Intervention: Kudo classification (NBI)
Number of subjects: 48
Study 21165822 — intervention group
Group type: COMPARATOR
Intervention: Vascular pattern intensity (VPI) (NBI)
Number of subjects: 48
Study 18499587 — intervention group
Group type: EXPERIMENTAL
Intervention: Epiaortic scanning (EAS)
Number of subjects: 113
Study 18499587 — intervention group
Group type: COMPARATOR
Intervention: Control group (manual aortic palpation without EAS)
Number of subjects: 113
Study 16556147 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroid withdrawal
Number of subjects: 120
Study 16556147 — intervention group
Group type: COMPARATOR
Intervention: Steroid maintenance
Number of subjects: 120
Study 15284215 — intervention group
Group type: EXPERIMENTAL
Intervention: Assisted hatching (AH) with a diode laser
Number of subjects: 426
Study 15284215 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunosuppressive/antibiotic treatment (IA)
Number of subjects: 426
Study 15284215 — intervention group
Group type: COMPARATOR
Intervention: Control group (no AH)
Number of subjects: 426
Study 11331055 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.625 mg of conjugated equine estrogens plus 2.5 mg of medroxyprogesterone acetate in 1 tablet daily (n = 1,380)
Number of subjects: 2763
Study 11331055 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 1,383)
Number of subjects: 2763
Study 9402552 — intervention group
Group type: EXPERIMENTAL
Intervention: Monte Carlo methods applied to two random samples of 500 values from two populations
Number of subjects: 100000
Study 9402552 — intervention group
Group type: EXPERIMENTAL
Intervention: Statistical tests (including Student's t test)
Number of subjects: 100000
Study 8387637 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadrantectomy followed by radiotherapy
Number of subjects: 567
Study 8387637 — intervention group
Group type: COMPARATOR
Intervention: Quadrantectomy without radiotherapy
Number of subjects: 567
Study 8387637 — intervention group
Group type: COMPARATOR
Intervention: Quadrantectomy without radiotherapy (age > 55)
Number of subjects: 567
Study 8387637 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment groups
Number of subjects: 567
Study 2447789 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protein diet (2 g.kg‐1.day‐1)
Number of subjects: 12
Study 2447789 — intervention group
Group type: COMPARATOR
Intervention: Low-protein diet (0.55 g.kg‐1.day‐1)
Number of subjects: 12
Study 29902472 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based moderate-intensity upper-body exercise intervention (n=13)
Number of subjects: 21
Study 29902472 — intervention group
Group type: COMPARATOR
Intervention: Lifestyle maintenance control group (n=8)
Number of subjects: 21
Study 27418820 — intervention group
Group type: EXPERIMENTAL
Intervention: IB/SAL-HFA pMDI, 20 μg qid
Number of subjects: 290
Study 27418820 — intervention group
Group type: COMPARATOR
Intervention: IB/SAL-CFC pMDI, 20 μg qid
Number of subjects: 290
Study 26037428 — intervention group
Group type: EXPERIMENTAL
Intervention: Pasireotide 900 μg subcutaneously twice daily for 7 days
Number of subjects: 300
Study 26037428 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 300
Study 22862906 — intervention group
Group type: EXPERIMENTAL
Intervention: Recapture Life intervention (six, weekly, 90-minute online group sessions led by a psychologist)
Number of subjects: 90
Study 22862906 — intervention group
Group type: COMPARATOR
Intervention: Peer-support group control (non-directive peer support delivered in an identical manner)
Number of subjects: 90
Study 20448584 — intervention group
Group type: EXPERIMENTAL
Intervention: Stainless Steel Crown (SSC)
Number of subjects: 154
Study 20448584 — intervention group
Group type: COMPARATOR
Intervention: Amalgam
Number of subjects: 154
Study 20448584 — intervention group
Group type: EXPERIMENTAL
Intervention: Failed restorations
Number of subjects: 154
Study 18989993 — intervention group
Group type: EXPERIMENTAL
Intervention: One 800 mg tablet (reference)
Number of subjects: 18
Study 18989993 — intervention group
Group type: EXPERIMENTAL
Intervention: Two 400 mg tablets (test)
Number of subjects: 18
Study 18989993 — intervention group
Group type: EXPERIMENTAL
Intervention: One 800 mg tablet in fed conditions (test)
Number of subjects: 18
Study 18989993 — intervention group
Group type: COMPARATOR
Intervention: One 800 mg tablet in fasting conditions (reference)
Number of subjects: 18
Study 16433404 — intervention group
Group type: EXPERIMENTAL
Intervention: 14% doxycycline gel (DOXY)
Number of subjects: 37
Study 16433404 — intervention group
Group type: COMPARATOR
Intervention: Scaling and root planing with a sonic scaler (SRP)
Number of subjects: 37
Study 12598265 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous epidural infusion of levobupivacaine 0.5%, 3 mL/h (n = 33)
Number of subjects: 60
Study 12598265 — intervention group
Group type: COMPARATOR
Intervention: Continuous epidural infusion of levobupivacaine 0.15%, 10 mL/h (n = 27)
Number of subjects: 60
Study 11079019 — intervention group
Group type: EXPERIMENTAL
Intervention: JPEG compression of raw images
Number of subjects: 0
Study 9380780 — intervention group
Group type: EXPERIMENTAL
Intervention: Inpatient psychotherapy
Number of subjects: 132
Study 9380780 — intervention group
Group type: COMPARATOR
Intervention: Outpatient psychotherapy
Number of subjects: 132
Study 8295811 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin oral suspension (7.5 mg/kg, max 500 mg, twice daily)
Number of subjects: 231
Study 8295811 — intervention group
Group type: COMPARATOR
Intervention: Cefadroxil oral suspension (15 mg/kg, max 1000 mg, twice daily)
Number of subjects: 231
Study 8295811 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin oral suspension
Number of subjects: 231
Study 8295811 — intervention group
Group type: COMPARATOR
Intervention: Cefadroxil oral suspension
Number of subjects: 231
Study 3552504 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral colonic lavage solution containing sodium sulfate and polyethylene glycol
Number of subjects: 34
Study 3552504 — intervention group
Group type: COMPARATOR
Intervention: Whole-gut irrigation using saline via a nasogastric tube
Number of subjects: 34
Study 31419994 — intervention group
Group type: EXPERIMENTAL
Intervention: AMBER care bundle (intervention)
Number of subjects: 65
Study 31419994 — intervention group
Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 65
Study 31419994 — intervention group
Group type: COMPARATOR
Intervention: Focus groups with health professionals
Number of subjects: 65
Study 26232542 — intervention group
Group type: EXPERIMENTAL
Intervention: 4CMenB vaccine (two doses, 1-month apart)
Number of subjects: 344
Study 24146363 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic training (AT), n = 20, 3 months of vigorous aerobic exercise, supervised three times per week
Number of subjects: 40
Study 24146363 — intervention group
Group type: COMPARATOR
Intervention: Nonaerobic (NA), n = 20, no aerobic exercise
Number of subjects: 40
Study 21334621 — intervention group
Group type: EXPERIMENTAL
Intervention: Antichlamydial treatment
Number of subjects: 600
Study 21334621 — intervention group
Group type: COMPARATOR
Intervention: No antichlamydial treatment
Number of subjects: 600
Study 21334621 — intervention group
Group type: COMPARATOR
Intervention: Seronegative participants who underwent seroconversion
Number of subjects: 600
Study 19825865 — intervention group
Group type: EXPERIMENTAL
Intervention: Newly presented unexplained complaints (UCs)
Number of subjects: 444
Study 19825865 — intervention group
Group type: COMPARATOR
Intervention: Being male
Number of subjects: 444
Study 19825865 — intervention group
Group type: COMPARATOR
Intervention: GPs' certainty about absence of serious disease
Number of subjects: 444
Study 19825865 — intervention group
Group type: COMPARATOR
Intervention: Duration of complaints >4 weeks before presentation
Number of subjects: 444
Study 19825865 — intervention group
Group type: COMPARATOR
Intervention: Musculoskeletal complaint at baseline
Number of subjects: 444
Study 19825865 — intervention group
Group type: COMPARATOR
Intervention: Passage of time
Number of subjects: 444
Study 19825865 — intervention group
Group type: COMPARATOR
Intervention: Musculoskeletal complaints
Number of subjects: 444
Study 19825865 — intervention group
Group type: COMPARATOR
Intervention: Presence of psychosocial factors
Number of subjects: 444
Study 17239430 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly topotecan 4.0 mg/m2 on days 1, 8, and 15 of a 28-day cycle
Number of subjects: 63